SnoRNAs: The promising targets for anti-tumor therapy
Journal of Pharmaceutical Analysis · 2024-11 · 14 (11) · 101064
DOI: 10.1016/j.jpha.2024.101064 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pharmaceutical Analysis, 2024-11. Verfasst von Xiaoyun Hu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, 110122, China. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Liaoning Provincial Natural Science Foundation, National Natural Science Foundation of China, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Recently, small nucleolar RNAs (snoRNAs) have transcended the genomic "noise" to emerge as pivotal molecular markers due to their essential roles in tumor progression. Substantial evidence indicates a strong association between snoRNAs and critical clinical features such as tumor pathology and drug resistance. Historically, snoRNA research has concentrated on two classical mechanisms: 2'-O-ribose methylation and pseudouridylation. This review specifically summarizes the novel regulatory mechanisms and functional patterns of snoRNAs in tumors, encompassing transcriptional, post-transcriptional, and post-translational regulation. We further discuss the synergistic effect between snoRNA host genes (SNHGs) and snoRNAs in tumor progression. More importantly, snoRNAs extensively contribute to the development of tumor cell resistance as oncogenes or tumor suppressor genes. Accordingly, we provide a comprehensive review of the clinical diagnosis and treatment associated with snoRNAs and explore their significant potential as novel drug targets.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, 110122, China.
- Liaoning Key Laboratory of Molecular Targeted Anti-tumor Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, Key Laboratory of Precision Diagnosis and Treatment o…
- Scientific Experimental Center, School of Pharmacy, China Medical University, Shenyang, 110122, China.
- The Second Department of Infectious Diseases, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.
- Department of Anorectal Surgery, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.
- Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA, 91016, USA.
Förderung
- Liaoning Provincial Natural Science Foundation
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
Zitieren
APA
Hu, X., Cui, W., Liu, M., Zhang, F., Zhao, Y., Zhang, M., Yin, Y., Li, Y., Che, Y., Zhu, X., Fan, Y., Deng, X., Wei, M., & Wu, H. (2024). SnoRNAs: The promising targets for anti-tumor therapy. Journal of Pharmaceutical Analysis, 14(11), 101064. https://doi.org/10.1016/j.jpha.2024.101064
Vancouver
Hu X, Cui W, Liu M, Zhang F, Zhao Y, Zhang M, et al. SnoRNAs: The promising targets for anti-tumor therapy. Journal of Pharmaceutical Analysis. 2024;14(11):101064. doi:10.1016/j.jpha.2024.101064
BibTeX
@article{Hu2024,
author = {Hu, Xiaoyun and Cui, Wanlin and Liu, Min and Zhang, Fangxiao and Zhao, Yingqi and Zhang, Mingrong and Yin, Yuhang and Li, Yalun and Che, Ying and Zhu, Xianglong and Fan, Yuxuan and Deng, Xiaolan and Wei, Minjie and Wu, Huizhe},
title = {SnoRNAs: The promising targets for anti-tumor therapy},
journal = {Journal of Pharmaceutical Analysis},
year = {2024},
volume = {14},
number = {11},
pages = {101064},
doi = {10.1016/j.jpha.2024.101064}
}
EUVIMED